Enhanced virulence effect of K1 polysaccharide in neonatal rats challenged withE. coli

Purified K1 polysaccharide enhanced the virulence of non-K1Escherichia coli species when given by orogastric feeding to neonatal rats. Neonatal rats developedE. coli bacteremia when K1 polysaccharide was given concomitantly with non-K1E. coli, whereasE. coli bacteremia did not develop when non-K1E. coli was given alone.E. coli K1 species did cause bacteremia and meningitis when fed to neonatal rats. The mechanism by which k1 polysaccharide enhances virulence can be studied with this model of bacteremia development in neonatal rats.     

Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial.

Sulphasalazine was first formulated by Svartz in the early 1940s, specifically for use as a remission inducing drug in rheumatoid arthritis. After the publication of an unfavourable trial, however, the drug was restricted to patients with ulcerative colitis. In the late 1970s sulphasalazine was re-examined in rheumatoid arthritis and favourable results reported in "open" trials. A double blind controlled trial was therefore conducted comparing enteric coated sulphasalazine and D-penicillamine in patients with active rheumatoid arthritis. A total of 63 patients were recruited in two centres; 31 were treated with sulphasalazine and 32 received penicillamine. After 16 weeks'' treatment both drugs had produced significant improvements in clinical score, pain score measured on a visual analogue scale, grip strength, Ritchie articular index, erythrocyte sedimentation rate, and serum C reactive protein concentration. Nausea was the major side effect in the sulphasalazine treated group. No potentially dangerous effects of sulphasalazine were encountered in contrast with those seen in the penicillamine group. The results suggest that sulphasalazine is an effective and safe drug capable of producing remissions in active rheumatoid arthritis. They also lend confidence to the use of preliminary "open" trials as a means of screening for remission inducing drugs in rheumatoid arthritis.     

Arsenazo I and tetramethylmurexide as optical calcium indicators

Calcium-binding stoichiometry, dissociation equilibrium constants at zero ionic strength (K⁰), and molar extinction difference coefficients (Δ?_λ) at the wavelength λ of the metallochromic indicators arsenazo I (ArsI) and tetramethylmurexide (TMX) were reevaluated with a computerized method based on mass conservation and thermodynamic consistency checks. This new method is shown to provide a more critical assessment of the assumed calcium-dye complexing model than is afforded by the commonly used reciprocal-plot method. The analyses of spectrophotometric Ca titrations confirm that both dyes form only 1:1 complexes in aqueous solution. For TMX, K⁰ = 1.3 × 10^?3m and Δ?₄₈₀ = 1.5 × 10⁴m^?1 cm^?1; for ArsI, K⁰ = 5.8 × 10^?3m and Δ?₅₆₂ = 1.8 × 10⁴m^?1 cm^?1 at pH 7.0 and T = 293°K. The discriminatory power of the analytical method is demonstrated by comparison of these results with those found for a different dye, arsenazo III, which complexes Ca in 1:1, 1:2, and 2:1 forms.     

Cryosurgery of lentigo maligna.

Lentigo maligna denotes flat, pigmented lesions predominantly in areas of actinic damage that have the propensity to become malignant. More than 10 years may pass before lentigo maligna evolves into an invasive neoplasma. As an invasive process, it is termed lentigo maligna melanoma (LMM), and it has the potential for both lymphatic and hematogenic metastases. Because of the size and location of the lesions, cosmetically unsatisfactory scars may result from conventional surgery. Therefore, alternative means of treatment, including cryosurgery, have been employed. We report on 12 patients suffering from lentigo maligna who had been treated successfully by cryosurgery between 1984 and 1990. The average follow-up period was 51.4 months, and the recurrence rate was 8.3 percent. Knowing that microinvasive components can be demonstrated in 15 percent of lentigo maligna lesions, we retrospectively reassessed our patients by immunohistochemical procedures with S-100 protein. Although intradermal microinvasion could be confirmed in one patient, no recurrence had been observed within 61 months of follow-up. Provided that patients are selected properly and extension of cryonecrosis is monitored, cryosurgery may prove an efficient alternative to conventional surgery in the treatment of lentigo maligna.     

Effects of energy level and monensin on reproductive performance and lactation of beef cows

This experiment consisted of a 2 year drylot study involving 80 multiparous, suckled beef cows (40 Angus and 40 Herefords). Experimental treatments (breed, monensin and year) were arranged in 2(3) factorial to evaluate the effect of breed and monensin on reproductive performance and lactation. Cows received 85% of the NRC total digestible nutrient (TDN) requirement for the first 56 days of the 140 day trial. Cows were synchronized with Synchro-Mate B and artificially inseminated 30 days into each trial with blood samples collected for luteinizing hormone (LH) analysis from one-half of each treatment group from 24 to 36 hours after implant removal. Progesterone determinations were made on plasma samples collected at day 9 and 16 after implant removal. On day 56, milk yield estimates were obtained by the weigh-suckle-weight technique. Following these collections, energy levels were increased by allowing ad lib consumption of forage. Calves, which were removed from the cows during feeding, were given access to a 75% TDN creep ration after day 56. Milk estimates were again evaluated at 140 days. Monensin supplementation did not result in a difference in cow weight change through the restricted energy period (first 56 days) or throughout the entire 140 day period. Milk yield estimates at 56 and 140 days and calf gains throught the trial, were unaffected by monensin supplementation. Monensin resulted in no effect on conception rate or services per conception. The time of the LH peak was shifted slightly forward by monensin although not significantly. Progesterone levels were not consistently affected by monensin supplementation.     

A haemagglutination inhibition test kit for routine analysis of erythropoietin.

A commercially available haemagglutination inhibition test kit for routine analysis of erythropoietin was shown to be unable to detect elevated levels of serum Epo.